Olivia C./LinkedIn
Mar 26, 2026, 17:14
Olivia C.: Pfizer’s mRNA BNT162b2 Vaccine Does Not Induce High Levels of Inflammation
Olivia C., Business Development Manager at Pfizer, shared a post on LinkedIn:
“Precise data on changes in hematological parameters in vaccinated patients are essential to accurately reflect advancements in medical technology.
Infections can cause significant changes in certain hematological parameters and exacerbate inflammatory responses, such as the neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), and ferritin levels.
In contrast, Pfizer’s mRNA-based BNT162b2 vaccine does not induce high levels of inflammation.”

Stay updated with Hemostasis Today.
-
Jun 23, 2026, 23:30Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis
-
Jun 23, 2026, 22:32How WFH Impacted the Bleeding Disorders Community in 2025
-
Jun 23, 2026, 22:03Erin VanDyke: A Journey Through VTE Leadership and Healthcare Transformation
-
Jun 23, 2026, 21:19Ahmed Koriesh: Join Us for Future of Stroke Care 2026
-
Jun 23, 2026, 20:30Aladdin Mohammad: Baseline IgG as a Key Predictor of Hypogammaglobulinaemia in AAV